Should I buy or sell Annovis Bio stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ANVS shares. View ANVS analyst ratings or view top-rated stocks .

What is Annovis Bio's stock price target for 2024?

4 brokers have issued 1-year target prices for Annovis Bio's shares. Their ANVS share price targets range from $9.00 to $36.00. On average, they predict the company's share price to reach $27.75 in the next twelve months. This suggests a possible upside of 175.8% from the stock's current price. View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts .

How have ANVS shares performed in 2024?

Annovis Bio's stock was trading at $18.70 at the start of the year. Since then, ANVS shares have decreased by 46.2% and is now trading at $10.06. View the best growth stocks for 2024 here .

Are investors shorting Annovis Bio?

Annovis Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 11.1% from the March 15th total of 1,350,000 shares. Based on an average trading volume of 268,500 shares, the short-interest ratio is currently 5.6 days. View Annovis Bio's Short Interest .

When is Annovis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANVS earnings forecast .

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.53.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , KushCo (KSHB) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Auxly Cannabis Group (CBWTF) , Novan (NOVN) , Sorrento Therapeutics (SRNE) , CNBX Pharmaceuticals (CNBX) and Enerplus (ERF) .

When did Annovis Bio IPO?

Annovis Bio (ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO.

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:ANVS

Annovis Bio (ANVS) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free ANVS Stock Alerts

$10.06

+0.21 (+2.13%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.62
▼
$10.18
50-Day Range: $8.47
▼
$12.20
52-Week Range: $5.42
▼
$22.49

Volume: 224,080 shs
Average Volume: 265,139 shs
Market Capitalization: $110.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.75

Get Annovis Bio alerts:

Annovis Bio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 175.8% Upside
$27.75 Price Target
Short Interest: Bearish
13.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.55
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.35) to ($2.82) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.66 out of 5 stars

Medical Sector

643rd out of 911 stocks

Pharmaceutical Preparations Industry

276th out of 411 stocks

3.4

Analyst's Opinion

Consensus Rating
Annovis Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Annovis Bio has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.62% of the outstanding shares of Annovis Bio have been sold short.
Short Interest Ratio / Days to Cover
Annovis Bio has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Annovis Bio has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Annovis Bio does not currently pay a dividend.
Dividend Growth
Annovis Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANVS.

3.1

News and Social Media Coverage

News Sentiment
Annovis Bio has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Annovis Bio this week, compared to 2 articles on an average week.
Search Interest
26 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 37% compared to the previous 30 days.
MarketBeat Follows
9 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Annovis Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.83% of the stock of Annovis Bio is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Annovis Bio are expected to grow in the coming year, from ($3.35) to ($2.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Annovis Bio is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Annovis Bio is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Annovis Bio Stock (NYSE:ANVS)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

ANVS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANVS Stock News Headlines

April 17, 2024 | finance.yahoo.com

Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals

April 17, 2024 | americanbankingnews.com

Annovis Bio Sees Unusually High Options Volume (NYSE:ANVS)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 15, 2024 | americanbankingnews.com

Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Growth in Short Interest

April 4, 2024 | msn.com

Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials

April 3, 2024 | msn.com

Annovis Bio's Buntanetap Shows Promise in Early Alzheimer’s Disease Study

April 2, 2024 | markets.businessinsider.com

Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer’s and Parkinson’s Treatments

April 2, 2024 | investorplace.com

ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 2, 2024 | globenewswire.com

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

April 1, 2024 | globenewswire.com

Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans

March 24, 2024 | msn.com

Annovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data Cleaning

March 21, 2024 | marketwatch.com

Annovis Bio Shares Up 31% on Progress Toward Reporting Data From Alzheimer's Study

March 20, 2024 | marketwatch.com

Annovis Bio Completes Data Cleaning for Buntanetap Study

March 20, 2024 | finance.yahoo.com

ANVS Jul 2024 30.000 call

March 20, 2024 | msn.com

Annovis to release efficacy data on Alzheimer's drug in April

March 20, 2024 | globenewswire.com

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease

March 18, 2024 | finance.yahoo.com

ANVS Oct 2024 5.000 put

March 18, 2024 | finance.yahoo.com

ANVS Apr 2024 20.000 call

March 18, 2024 | msn.com

Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?

March 15, 2024 | 247wallst.com

$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year

March 6, 2024 | investorplace.com

Sell Signal: 3 Stocks to Unload Before the Bubble Bursts

March 4, 2024 | msn.com

Annovis Bio to Shed Light on Neurodegenerative Diseases at International Conference

February 29, 2024 | stockhouse.com

Annovis Bio Announces Participation in Forum Discussion at AD/PD(TM) 2024

February 28, 2024 | msn.com

Brookline Capital Downgrades Annovis Bio (ANVS)

February 28, 2024 | markets.businessinsider.com

Maintaining Hold on Annovis Bio Amid Phase 3 Parkinson’s Trial Concerns and Financial Uncertainties

February 28, 2024 | msn.com

Annovis Bio falls after Brookline Capital downgrades on PD trial complications

See More Headlines

Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:ANVS
CUSIP: N/A
CIK: 1477845
Web: www.annovisbio.com
Phone: 610-727-3913
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.75
High Stock Price Target: $36.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +178.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,200,000.00
Net Margins: N/A
Pretax Margin: -74,496.43%
Return on Equity: -446.06%
Return on Assets: -257.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.39
Quick Ratio: 2.39

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.73) per share
Price / Book: -13.67

Miscellaneous

Outstanding Shares: 11,010,000
Free Float: 6,794,000
Market Cap: $109.88 million
Optionable: Optionable
Beta: 1.59

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Maria L. Maccecchini Ph.D. (Age 73)
Founder, CEO, President & Executive Director
Comp: $965.6k
Mr. Henry Hagopian III (Age 56)
M.B.A., Chief Financial Officer
Comp: $510.05k
Dr. Cheng Fang Ph.D.
Senior Vice President of Research & Development
Ms. Eve M. Damiano M.S.
RAC, Senior Vice President of Regulatory Operations
Ms. Melissa Gaines
Senior Vice President of Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Annovis Bio stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ANVS shares.
View ANVS analyst ratings or view top-rated stocks.
What is Annovis Bio's stock price target for 2024?: 4 brokers have issued 1-year target prices for Annovis Bio's shares. Their ANVS share price targets range from $9.00 to $36.00. On average, they predict the company's share price to reach $27.75 in the next twelve months. This suggests a possible upside of 175.8% from the stock's current price.
View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts.
How have ANVS shares performed in 2024?: Annovis Bio's stock was trading at $18.70 at the start of the year. Since then, ANVS shares have decreased by 46.2% and is now trading at $10.06.
View the best growth stocks for 2024 here.
Are investors shorting Annovis Bio?: Annovis Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 11.1% from the March 15th total of 1,350,000 shares. Based on an average trading volume of 268,500 shares, the short-interest ratio is currently 5.6 days.
View Annovis Bio's Short Interest.
When is Annovis Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ANVS earnings forecast.

How were Annovis Bio's earnings last quarter?: Annovis Bio, Inc. (NYSE:ANVS) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.53.
What other stocks do shareholders of Annovis Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).
When did Annovis Bio IPO?: Annovis Bio (ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO.
How do I buy shares of Annovis Bio?: Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ANVS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial